Loft S, Otton S V, Lennard M S, Tucker G T, Poulsen H E
Department of Pharmacology, University of Copenhagen, Denmark.
Biochem Pharmacol. 1991 Apr 15;41(8):1127-34. doi: 10.1016/0006-2952(91)90650-t.
The metabolism of metronidazole was studied in microsomes isolated from livers of human kidney donors. The formation of the major in vivo metabolite, hydroxymetronidazole, proceeded according to biphasic kinetics, suggesting the involvement of at least two enzymatic sites. The affinity constant (Km) of the high affinity site ranged from 140 to 320 microM and metabolism at this site contributed more than 75% of the intrinsic clearance. Thus, at therapeutic doses of metronidazole most of the hydroxylation in vivo should be associated with this site. Antipyrine, cimetidine, alpha-naphthoflavone, caffeine, theophylline, mephenytoin, tolbutamide, quinidine, acetone and nifedipine were poor inhibitors of the formation of hydroxymetronidazole by human liver microsomes. Propranolol (500 microM) inhibited the hydroxylation rate by 70%. Phenacetin inhibited metronidazole hydroxylation with a competitive inhibition constant (Ki) of 4-5 microM. However, metronidazole did not inhibit the O-deethylation of phenacetin. It is concluded that cytochromes P450 IA2, IIC9, IIC10, IID6, IIE1 and IIIA3 do not contribute significantly to the high affinity hydroxylation of metronidazole in man.
在从人类肾脏供体肝脏中分离出的微粒体中研究了甲硝唑的代谢情况。体内主要代谢产物羟基甲硝唑的形成遵循双相动力学,这表明至少有两个酶作用位点参与其中。高亲和力位点的亲和常数(Km)在140至320微摩尔之间,该位点的代谢作用对内在清除率的贡献超过75%。因此,在甲硝唑治疗剂量下,体内大部分羟基化反应应与该位点相关。安替比林、西咪替丁、α-萘黄酮、咖啡因、茶碱、美芬妥英、甲苯磺丁脲、奎尼丁、丙酮和硝苯地平对人肝微粒体形成羟基甲硝唑的抑制作用较弱。普萘洛尔(500微摩尔)使羟基化速率降低70%。非那西丁抑制甲硝唑羟基化,其竞争性抑制常数(Ki)为4 - 5微摩尔。然而,甲硝唑并不抑制非那西丁的O - 去乙基化反应。得出的结论是,细胞色素P450 IA2、IIC9、IIC10、IID6、IIE1和IIIA3对人体中甲硝唑的高亲和力羟基化反应贡献不大。